pd-l1 t-hank (ImmunityBio Inc)
90
Structured Review
ImmunityBio Inc
pd-l1 t-hank
Pd L1 T Hank, supplied by ImmunityBio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd-l1+t-hank/pd+l1+t+hank/nct06239220-7-3-0
Average 90 stars, based on 1 article reviews
Pd L1 T Hank, supplied by ImmunityBio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pd-l1+t-hank/pd+l1+t+hank/nct06239220-7-3-0
Average 90 stars, based on 1 article reviews
pd-l1 t-hank - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Modification:Article Title: Next Generation Natural Killer Cells for Cancer Immunotherapy Article Snippet: , PD-L1 , Pancreatic Cancer , NK-92 cell line , PD-L1 t-haNK , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-1/PD-L1 , QUILT-3.055, Anti-PD-1, Anti-PD-L1, PD-L1 t-haNK , Cancers previously treated with PD-1/PD-L1 Immune Checkpoint Inhibitors , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , QUILT-3.064, PD-L1 t-haNK , Advanced or metastatic solid tumors , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , Sacituzumab, PD-L1 t-haNK, N-803 , Advanced Triple Negative Breast Cancer , Article Title: Research progress of interleukin-15 in cancer immunotherapy Article Snippet: , , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , PD-L1 t-haNK, N-803, Aldoxorubicin , Pancreatic Cancer , Article Title: A Phase 2 Trial of PD-L1 t-haNK, N-803 IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505) Article Snippet: Control:Article Title: Next Generation Natural Killer Cells for Cancer Immunotherapy Article Snippet: , PD-L1 , Pancreatic Cancer , NK-92 cell line , PD-L1 t-haNK , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-1/PD-L1 , QUILT-3.055, Anti-PD-1, Anti-PD-L1, PD-L1 t-haNK , Cancers previously treated with PD-1/PD-L1 Immune Checkpoint Inhibitors , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , QUILT-3.064, PD-L1 t-haNK , Advanced or metastatic solid tumors , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , Sacituzumab, PD-L1 t-haNK, N-803 , Advanced Triple Negative Breast Cancer , Article Title: Research progress of interleukin-15 in cancer immunotherapy Article Snippet: , , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , PD-L1 t-haNK, N-803, Aldoxorubicin , Pancreatic Cancer , Article Title: A Phase 2 Trial of PD-L1 t-haNK, N-803 IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505) Article Snippet: Activity Assay:Article Title: Next Generation Natural Killer Cells for Cancer Immunotherapy Article Snippet: , PD-L1 , Pancreatic Cancer , NK-92 cell line , PD-L1 t-haNK , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-1/PD-L1 , QUILT-3.055, Anti-PD-1, Anti-PD-L1, PD-L1 t-haNK , Cancers previously treated with PD-1/PD-L1 Immune Checkpoint Inhibitors , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , QUILT-3.064, PD-L1 t-haNK , Advanced or metastatic solid tumors , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , Sacituzumab, PD-L1 t-haNK, N-803 , Advanced Triple Negative Breast Cancer , Article Title: Research progress of interleukin-15 in cancer immunotherapy Article Snippet: , , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , PD-L1 t-haNK, N-803, Aldoxorubicin , Pancreatic Cancer , Article Title: A Phase 2 Trial of PD-L1 t-haNK, N-803 IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505) Article Snippet: Biomarker Discovery:Article Title: Next Generation Natural Killer Cells for Cancer Immunotherapy Article Snippet: , PD-L1 , Pancreatic Cancer , NK-92 cell line , PD-L1 t-haNK , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-1/PD-L1 , QUILT-3.055, Anti-PD-1, Anti-PD-L1, PD-L1 t-haNK , Cancers previously treated with PD-1/PD-L1 Immune Checkpoint Inhibitors , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , QUILT-3.064, PD-L1 t-haNK , Advanced or metastatic solid tumors , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , Sacituzumab, PD-L1 t-haNK, N-803 , Advanced Triple Negative Breast Cancer , Article Title: Research progress of interleukin-15 in cancer immunotherapy Article Snippet: , , Article Title: Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy Article Snippet: PD-L1 , PD-L1 t-haNK, N-803, Aldoxorubicin , Pancreatic Cancer , Article Title: A Phase 2 Trial of PD-L1 t-haNK, N-803 IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505) Article Snippet: |
